Game Changing AI Applications from Healthcare to Marketing to Gaming
Avant Technologies (OTCQB: AVAI) and its partner Ainnova Tech have secured exclusive licenses for four AI-driven healthcare algorithms from a major Asian healthcare institution. These algorithms, validated with over 2 million patient data points, focus on early detection of cardiovascular risk, prediabetes, Type 2 diabetes, fatty liver disease, and chronic kidney disease. The solutions will be integrated into Ainnova's VisionAI platform, with plans to launch in Latin American markets and pursue FDA clearance in 2025 for US market entry.
The broader AI market reached $184 billion in 2024, showing a $50 billion increase from 2023, with projections to exceed $826 billion by 2030. Healthcare remains a critical application area for AI, focusing on improving diagnostics, personalizing treatment plans, and optimizing patient care.
Avant Technologies (OTCQB: AVAI) e il suo partner Ainnova Tech hanno ottenuto licenze esclusive per quattro algoritmi sanitari basati sull'IA da una importante istituzione sanitaria asiatica. Questi algoritmi, validati con oltre 2 milioni di punti dati dei pazienti, si concentrano sulla rilevazione precoce del rischio cardiovascolare, della prediabete, del diabete di tipo 2, della steatosi epatica e delle malattie renali croniche. Le soluzioni saranno integrate nella piattaforma VisionAI di Ainnova, con piani di lancio nei mercati dell'America Latina e l'obiettivo di ottenere l'approvazione della FDA nel 2025 per entrare nel mercato statunitense.
Il mercato globale dell'IA ha raggiunto i 184 miliardi di dollari nel 2024, mostrando un aumento di 50 miliardi rispetto al 2023, con previsioni che supereranno i 826 miliardi entro il 2030. La sanità rimane un'area critica di applicazione per l'IA, concentrandosi sul miglioramento della diagnostica, sulla personalizzazione dei piani di trattamento e sull'ottimizzazione della cura dei pazienti.
Avant Technologies (OTCQB: AVAI) y su socio Ainnova Tech han asegurado licencias exclusivas para cuatro algoritmos de atención médica impulsados por IA de una importante institución de salud asiática. Estos algoritmos, validados con más de 2 millones de puntos de datos de pacientes, se centran en la detección temprana del riesgo cardiovascular, la prediabetes, la diabetes tipo 2, la enfermedad del hígado graso y la enfermedad renal crónica. Las soluciones se integrarán en la plataforma VisionAI de Ainnova, con planes de lanzamiento en los mercados de América Latina y con el propósito de obtener la autorización de la FDA en 2025 para su entrada en el mercado estadounidense.
El mercado global de IA alcanzó los 184 mil millones de dólares en 2024, mostrando un aumento de 50 mil millones desde 2023, con proyecciones que excederán los 826 mil millones para 2030. La atención médica sigue siendo un área crítica de aplicación para la IA, enfocándose en mejorar la diagnóstico, personalizar los planes de tratamiento y optimizar la atención al paciente.
Avant Technologies (OTCQB: AVAI)와 파트너 Ainnova Tech는 아시아의 주요 건강 기관으로부터 AI 기반 건강 알고리즘 4개에 대한 독점 라이센스를 확보했습니다. 이 알고리즘은 200만 개 이상의 환자 데이터 포인트로 검증되었으며, 심혈관 위험의 조기 발견, 당뇨병 전 단계, 제2형 당뇨병, 지방간 질환 및 만성 신장 질환에 중점을 두고 있습니다. 이 솔루션은 Ainnova의 VisionAI 플랫폼에 통합될 예정이며, 라틴 아메리카 시장에 출시할 계획과 2025년 미국 시장 진출을 위한 FDA 승인 신청을 목표로 하고 있습니다.
2024년 글로벌 AI 시장은 1,840억 달러에 달하며, 2023년 대비 500억 달러 증가했으며, 2030년까지 8,260억 달러를 초과할 것으로 예상됩니다. 의료 분야는 AI의 주요 응용 분야로, 진단 개선, 치료 계획 개인화 및 환자 관리 최적화에 중점을 두고 있습니다.
Avant Technologies (OTCQB: AVAI) et son partenaire Ainnova Tech ont obtenu des licences exclusives pour quatre algorithmes de santé pilotés par l'IA d'une grande institution de santé asiatique. Ces algorithmes, validés par plus de 2 millions de points de données de patients, se concentrent sur la détection précoce des risques cardiovasculaires, du prédiabète, du diabète de type 2, de la stéatose hépatique et des maladies rénales chroniques. Les solutions seront intégrées à la plateforme VisionAI d'Ainnova, avec des projets de lancement sur les marchés d'Amérique latine et l'objectif d'obtenir l'autorisation de la FDA en 2025 pour entrer sur le marché américain.
Le marché mondial de l'IA a atteint 184 milliards de dollars en 2024, enregistrant une augmentation de 50 milliards par rapport à 2023, avec des prévisions dépassant les 826 milliards d'ici 2030. La santé reste un domaine d'application critique pour l'IA, axé sur l'amélioration des diagnostics, la personnalisation des plans de traitement et l'optimisation des soins aux patients.
Avant Technologies (OTCQB: AVAI) und ihr Partner Ainnova Tech haben exklusive Lizenzen für vier KI-gesteuerte Gesundheitsalgorithmen von einer wichtigen asiatischen Gesundheitseinrichtung gesichert. Diese Algorithmen, die mit über 2 Millionen Patientendaten validiert wurden, konzentrieren sich auf die frühzeitige Erkennung von kardiovaskulären Risiken, Prädiabetes, Typ-2-Diabetes, Fettlebererkrankung und chronischer Nierenerkrankung. Die Lösungen werden in die VisionAI-Plattform von Ainnova integriert, mit Plänen für einen Markteintritt in Lateinamerika und dem Ziel, 2025 die FDA-Zulassung für den Eintritt in den US-Markt zu erhalten.
Der weltweite KI-Markt erreichte 2024 ein Volumen von 184 Milliarden Dollar, was einem Anstieg von 50 Milliarden Dollar im Vergleich zu 2023 entspricht, mit Prognosen, die darauf hindeuten, dass er bis 2030 826 Milliarden Dollar überschreiten wird. Das Gesundheitswesen bleibt ein kritischer Anwendungsbereich für KI, mit dem Fokus auf der Verbesserung der Diagnostik, der Personalisierung von Behandlungsplänen und der Optimierung der Patientenversorgung.
- Secured exclusive license for four validated AI healthcare algorithms
- Algorithms validated across 2 million+ patient dataset
- Planned FDA clearance pursuit in 2025 for US market entry
- Strategic expansion into Latin American markets (Mexico and Brazil)
- FDA approval not yet secured, representing regulatory uncertainty
- Revenue generation timeline unclear
- Significant competition in the healthcare AI space
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - December 18, 2024) - Investorideas.com, a global news source and expert investing resource covering AI stocks issues a snapshot for the sector looking at some of the top AI applications, featuring Avant Technologies, Inc. (OTCQB: AVAI), an emerging technology company developing solutions in artificial intelligence in healthcare.
Read the full article on Investorideas.com
https://www.investorideas.com/news/2024/technology/12180AI-Applications.asp
Statista.com says, "The market for artificial intelligence grew beyond 184 billion U.S. dollars in 2024, a considerable jump of nearly 50 billion compared to 2023. This staggering growth is expected to continue with the market racing past 826 billion U.S. dollars in 2030."
AI is being integrated into almost every aspect of our daily lives and moving technology ahead at warp speed.
According to Simplilearn, "One of the critical AI applications is its integration with the healthcare and medical field. AI transforms healthcare by improving diagnostics, personalizing treatment plans, and optimizing patient care. AI algorithms can analyze medical images, predict disease outbreaks, and assist in drug discovery, enhancing the overall quality of healthcare services."
Focusing on AI and healthcare, Avant Technologies Inc. (OTCQB: AVAI), and its partner, Ainnova Tech, Inc., a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), just announced Ainnova's acquisition of an exclusive license for four groundbreaking, AI-driven algorithms from one of Asia's most respected and largest healthcare institutions. These solutions, validated across diverse geographies, ethnicities, and socioeconomic populations with data from over 2 million patients, will join Ainnova's existing diabetic retinopathy and retinal disease detection solutions.
From the news: The four algorithms include early detection for cardiovascular risk, prediabetes and Type 2 diabetes, fatty liver disease and chronic kidney disease. Combined with Ainnova's existing retinal disease detection tools, these new algorithms will be used with Ainnova's powerful cutting-edge AI platform, VisionAI, to detect the early markers of these diseases quickly and accurately by applying AI.
Continued: The acquisition of an exclusive license to use four advanced algorithms in the Americas offers Ainnova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, a robust platform for primary care providers to streamline early risk screening and improve patient care in the United States.
Continued: Ainnova will introduce these cutting-edge solutions in Latin America with strategic partners in primary healthcare services across key markets such as Mexico and Brazil. AAC expects to build on Ainnova's regional expansion by securing clearance from the US Food and Drug Administration (FDA) in 2025 to then introduce these solutions in the US market.
Continued: While explaining that these efforts aim to transform the current approach to preventive care by providing accessible, efficient, and impactful health screening solutions, Ainnova's Chief Executive Officer, Vinicio Vargas, said, "This license represents a pivotal moment for Ainnova and for its partnership with Avant as it allows us to bring world class, validated solutions to the Americas. This effort not only complements our current solutions, but it also aligns with our ongoing R&D initiatives to continue incorporating new diseases that can be detected quickly and affordably, pushing the boundaries of preventive care, and making healthcare more inclusive and accessible to all."
Continued: "The licensed algorithms enhance the company's capabilities to empower healthcare providers with comprehensive, fast, and accessible tools for early disease detection. Using simple patient datapoints - such as demographics and lifestyle attributes, and routine measures like blood pressure - these algorithms enable rapid risk screening, facilitating timely specialist referrals and improving health outcomes."
Key Features and Benefits of the New Algorithms:
Cardiovascular Risk Assessment:
Prediabetes and Type 2 Diabetes Prediction:
Predicts the three-year risk of diabetes with an AUC of 0.861, using demographic and lifestyle data.
Provides tailored care plans and actionable insights to prevent disease progression.
Liver Fibrosis Screening:
Identifies patients at risk of advanced liver fibrosis with accuracy exceeding
88% .Supports timely referral and management of non-alcoholic fatty liver disease.
Chronic Kidney Disease (CKD) Monitoring:
Predicts CKD progression and supports preventive interventions to slow disease advancement.
Guides care through integrated analysis of clinical and laboratory data.
Continued: Mr. Vargas added, "This robust AI platform marks a significant step toward global adoption, ensuring that advanced AI tools are accessible to healthcare systems everywhere."
Continued: Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica and Houston, Texas, founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
Taking a different strategy with AI and healthcare, SoundHound AI, Inc., a global leader in voice artificial intelligence, recently announced that its Amelia Conversational AI Platform has been named a Leader in the 2024 Frost Radar™: Enterprise Conversational AI in Healthcare.
From the news: According to Frost & Sullivan, the market for enterprise conversational AI in healthcare will reach
Continued: By leveraging sophisticated natural language processing, natural language understanding, and fine-tuned large language models, SoundHound's Amelia Conversational AI Platform enables dynamic, contextually rich interactions that improve patient engagement, streamline administrative workflows, and enhance employee support. For patients, the platform offers solutions like scheduling and managing appointments, pre-registration, medication refills, and finding locations or doctors across multiple channels - offloading work from call centers and scheduling employees. The solution also supports employees by responding to common service and help desk requests, including IT support.
An AI company with offerings spanning health and wellness as well as gaming, Gaxos.ai Inc.
a company developing artificial intelligence applications across various sectors, just announced that the Company successfully integrated Recraft AI into their artificial intelligence solution for game developers and publishers, Gaxos Labs.
From the news: "We are pleased to add another great tool into our Gaxos Labs ecosystem," said Vadim Mats, CEO of Gaxos. "Game development is a labor-intensive process and the addition of tools that make the process simpler advances our goal of being the all-in-one artificial intelligence solution for game developers and publishers."
Gaxos.ai isn't just developing applications; it's redefining the human-AI relationship. Our offerings span health and wellness as well as gaming."
Seen as a real game-changer in marketing/advertising by most analyst following AI, AppLovin makes technologies that help businesses of every size connect to their ideal customers. The company provides end-to-end software and AI solutions for businesses to reach, monetize and grow their global audiences
Also in the gaming market, AppLovin said earlier this year, "The best way for gaming developers to increase long-term retention is to make their game or app feel like it's designed especially for their players," noted Daniel Tchernahovsky, VP of International Business Development at AppLovin. "AI enables developers to segment users and customize game progression so it feels as if the game's level of difficulty has been uniquely calibrated to a user."
The company reached
According to recent notes from Zacks, "AppLovin Corporation APP has been one of the standout performers in 2024, with its stock price surging by a monstrous
Other top applications for AI include education, automobiles and social media.
AI is being integrated into everything, evolving every business sector to new levels not preciously imagined.
Research more AI stocks with Investorideas.com free stock directory
https://www.investorideas.com/TSS/Stock_List.asp#Robotics
About Investorideas.com - Big Investing Ideas
Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.
Disclaimer/Disclosure: This article featuring Avant Technologies, Inc. (AVAI) is part of Investorideas.com paid for article content creation. This is not investment opinion. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure: Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
More disclaime: https://www.investorideas.com/About/Disclaimer.asp
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on Twitter @investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.
800 665 0411
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/234263
FAQ
What AI algorithms did AVAI acquire licenses for in December 2024?
When does AVAI plan to obtain FDA clearance for its AI healthcare solutions?
How many patient data points were used to validate AVAI's new AI algorithms?
What is the accuracy rate of AVAI's liver fibrosis screening algorithm?
Which Latin American markets is AVAI targeting for initial deployment?
